FDA approves Israeli drug for coronavirus treatment trials

Researchers are hoping that Aviptadil will be able to take on the so-called Acute Respiratory Distress Syndrome (ARDS) -- a condition responsible for about 50% of COVID-19 fatalities

i24NEWS|
The U.S. Food and Drug Administration on Sunday has cleared NeuroRx, a US-Israeli pharmaceutical company, and Relief Therapeutics, a Swiss drug development company, for phase two trials for a drug that could take on a deadly condition associated with COVID-19.

  • Follow Ynetnews on Facebook and Twitter

  • The two companies announced that the FDA issued a "study may proceed" letter -- which does not amount to a full-fledged drug approval -- for the substance to be tried on COVID-19 patients.
    2 View gallery
    צרפת נגיף קורונה מטפלים בחולים שטרסבורג
    צרפת נגיף קורונה מטפלים בחולים שטרסבורג
    Medics treating a coronavirus victim in France
    (Photo: Reuters)
    The drug in question, Aviptadil, is a synthetic form of a neuropeptide hormone that works to enable communications between neurons in the human nervous system.
    The researchers are hoping that Aviptadil will be able to take on the so-called Acute Respiratory Distress Syndrome (ARDS) -- a condition responsible for about 50% of COVID-19 fatalities.

    2 View gallery
    צרפת נגיף קורונה חולים ליד פריז
    צרפת נגיף קורונה חולים ליד פריז
    Coronavirus patient outside Paris hospital
    (Photo: Reuters)
    ARDS is a respiratory system failure induced by a rapid and severe lung inflammation, with breath shortness -- a symptom COVID-19 is widely associated with -- among its key signs.
    It effectively brings to a halt the oxygen and carbon dioxide exchange in the patient's lungs, necessitating the use of an artificial lung ventilation machine.

    Comments
    The commenter agrees to the privacy policy of Ynet News and agrees not to submit comments that violate the terms of use, including incitement, libel and expressions that exceed the accepted norms of freedom of speech.